Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials

Minjie Gao; Lu Gao; Guang Yang; Yi Tao; Tompkins, Van S.; Xiaosong Wu; Hongwei Xu; Fenghuang Zhan; Jumei Shi
June 2014
International Journal of Clinical & Experimental Pathology;2014, Vol. 7 Issue 6, p3073
Academic Journal
No abstract available.


Related Articles

  • Lenalidomide: A Review of Its Continuous Use in Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Stem-Cell Transplantation. McCormack, Paul // Drugs & Aging;May2015, Vol. 32 Issue 5, p409 

    Lenalidomide (Revlimid) is a second-generation immunomodulatory drug structurally related to thalidomide, with improved efficacy and tolerability, for which the label in the EU was recently expanded to include continuous therapy in patients with previously untreated multiple myeloma not eligible...

  • New England Journal of Medicine Reports on Three Phase III REVLIMID(r) (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma.  // Biomedical Market Newsletter;5/12/2012, Vol. 21, p1 

    The article informs that phase III clinical trials of REVLIMID, lenalidomide drug, from Celgene Corp. were published online in the May 10, 2012 edition of the New England Journal of Medicine. It provides information that phase III clinical trials were performed to evaluate the use of continuous...

  • Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma. Attal, Michel; Lauwers-Cances, Valerie; Marit, Gerald; Caillot, Denis; Moreau, Philippe; Facon, Thierry; Stoppa, Anne Marie; Hulin, Cyrille; Benboubker, Lofti; Garderet, Laurent; Decaux, Olivier; Leyvraz, Serge; Vekemans, Marie-Christiane; Voillat, Laurent; Michallet, Mauricette; Pegourie, Brigitte; Dumontet, Charles; Roussel, Murielle; Leleu, Xavier; Mathiot, Claire // New England Journal of Medicine;5/10/2012, Vol. 366 Issue 19, p1782 

    Background: High-dose chemotherapy with autologous stem-cell transplantation is a standard treatment for young patients with multiple myeloma. Residual disease is almost always present after transplantation and is responsible for relapse. This phase 3, placebo-controlled trial investigated the...

  • Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. McCarthy, Philip L.; Owzar, Kouros; Hofmeister, Craig C.; Hurd, David D.; Hassoun, Hani; Richardson, Paul G.; Giralt, Sergio; Stadtmauer, Edward A.; Weisdorf, Daniel J.; Vij, Ravi; Moreb, Jan S.; Callander, Natalie Scott; Van Besien, Koen; Gentile, Teresa; Isola, Luis; Maziarz, Richard T.; Gabriel, Don A.; Bashey, Asad; Landau, Heather; Martin, Thomas // New England Journal of Medicine;5/10/2012, Vol. 366 Issue 19, p1770 

    Background: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. Methods: Between April 2005 and July 2009, we randomly assigned 460 patients who were...

  • Lenalidomide in Myeloma � A High-Maintenance Friend. Badros, Ashraf Z. // New England Journal of Medicine;5/10/2012, Vol. 366 Issue 19, p1836 

    The article discusses the results of three double-blind, randomized trials that assessed lenalidomide maintenance therapy for patients with myeloma. All studies showed that lenalidomide maintenance significantly improved progression-free survival or time to progression. Patients who had...

  • Maintenance therapy in multiple myeloma. Harousseau, Jean-Luc // Hematology Reviews;2009, Vol. 1 Issue 2, p65 

    The article discusses the maintenance therapy for multiple myeloma. It states that thalidomide is used as a maintenance therapy for patients with multiple myeloma (MM) which undergo autologous stem-cell transplantation (ASCT). It cites that Lenalidomide is more tolerated by patients than...

  • How to select among available options for the treatment of multiple myeloma. Harousseau, J. L. // Annals of Oncology;Sep2012 Supplement 10, Vol. 23 Issue suppl_10, px334 

    The introduction of novel agents (thalidomide, bortezomib and lenalidomide) in the frontline therapy of multiple myeloma has markedly improved the outcome both in younger patients who are candidates for high-dose therapy plus autologous stem-cell transplantation (HDT/aSCT) and in elderly...

  • Multiple Myeloma.  // Annals of Internal Medicine;9/21/2004, Vol. 141 Issue 6, p458 

    This article briefly describes a study revealing double autologous stem-cell transplantation in improving overall survival among patients with multiple myeloma. Multiple myeloma is the second most common type of hematologic cancer after non-Hodgkin lymphoma. Two earlier trials that incorporated...

  • High-Dose Chemotherapy Shows Promise Against Multiple Myeloma. Wang, Linda // JNCI: Journal of the National Cancer Institute;6/4/2003, Vol. 95 Issue 11, p777 

    Reports findings of a randomized trial that high-dose chemotherapy combined with an autologous stem-cell transplant appears to be a more effective treatment for multiple myeloma than standard chemotherapy alone. Use of high-dose chemotherapy with stem-cell transplantation as a first-line...

  • Lenalidomide maintenance extends PFS in multiple myeloma after transplantation. Leiser, Mark; Southall, Jennifer; Stott, Bob; Todak, Alexandra // Hem/Onc Today;1/10/2014, Vol. 15 Issue 1, p17 

    The article discusses the study presented at American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana on December 7-10, 2013, that found progression-free survival (PFS) benefits in multiple myeloma patients who received first-line autologous stem-cell transplant and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics